Gain expert insight on the use of ICIs either as monotherapy or in combination with targeted agents when managing patients with gastric or GEJ cancer, as informed by recent data from the 2019 Gastrointestinal Cancers Symposium.
With widening use of immune checkpoint inhibitors in patients with gastroesophageal cancer, it is critical for clinicians to stay abreast of the unique adverse events associated with these agents
Which of our patients with advanced gastric/GEJ cancers are most likely to benefit from later-line treatment with PD-1 inhibitors? Here’s my take on applying the latest evidence to the clinic.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.